Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Sarcoma
>>
Tyrosine Kinase Inhibitors
>>
Phase 2
«
1
2
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
3
6
9
12
15
18
21
24
27
30
AMG 337
/ ImmunityBio, Amgen
ENMD-2076
/ CASI
Enhertu
(fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Jivadco
(trastuzumab duocarmazine) / Byondis, Medac
Lovaxin B
(OST-HER2) / OS Therapies
Nerlynx
(neratinib) / Puma
Orpathys
(savolitinib) / AstraZeneca, Hutchmed
Pemazyre
(pemigatinib) / Incyte
Tagrisso
(osimertinib) / AstraZeneca
Truseltiq
(infigratinib) / BridgeBio, Pfizer, Xediton Pharma
Tukysa
(tucatinib) / Pfizer
Vonjo
(pacritinib) / SOBI
XL820
/ Exelixis
anvatabart opadotin
(JNJ-0683) / J&J
brivanib alaninate
(BMS-582664) / ZAI Lab
emvododstat
(PTC299) / PTC Therap
enapotamab vedotin
(HuMax-AXL-ADC) / Genmab
mecbotamab vedotin
(BA3011) / BioAtla
picropodophyllin
(AXL1717) / Axelar
rogaratinib
(BAY 1163877) / Bayer
seribantumab
(MM-121) / Elevation Oncology
sitravatinib
(MGCD516) / BeiGene
thrombospondin-1 mimetic
(ABT-510) / AbbVie
tinengotinib
(TT-00420) / TransThera Biosci
zilovertamab vedotin
(MK-2140) / Merck (MSD)
zotiraciclib
(TG02) / Cothera Biosci
«
1
2
